Immunology / Virology & Vaccines

#Funding #Immunology / Virology & Vaccines #Investment #mRNA #mRNA-based vaccines

Funding injection for Strep A vaccine research

A research effort to develop an mRNA vaccine against Group A Streptococcus (Strep A) has secured almost $8 million in funding.  The Leducq Foundation has announced support for the University of Queensland-led project that could reduce Strep A infections, which cause more than 500,000 deaths a year… Read More

#News

Covid-19 vaccination
#Cardiovascular disease #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines

Covid-19 vaccination reduces risk of cardiac events

Researchers have revealed that vaccination against Covid-19 is associated with fewer heart attacks, strokes, and other cardiovascular issues among people who were infected with SARS-CoV-2.  The conclusions are based on analysis of the most extensive datasets in the United States by a team from the Icahn School… Read More

#News #Trending News

Hepatitis B
#hepatitis #Immunology / Virology & Vaccines #Immunotherapy #Phase II trial #siRNA #VBI Vaccines

Hepatitis B combination restores antibody and T cell responses

Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients.   The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More

#News #Trending News

#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines

Optimising AAV capsid purification through improved analytics

Listen to this article on the DDW Podcast: Svea Cheeseman, Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. As demand for AAV gene therapies increases, it is… Read More

#Exclusive Content

Mosquito
#Immunology / Virology & Vaccines #MHRA #Phase III trial #Takeda #Vaccine candidate

UK approval for dengue virus vaccine candidate

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019… Read More

#News

Ebola virus
#Animal testing #Ebola virus #Immunology / Virology & Vaccines #National Institute of Allergy and Infectious Diseases #National Institutes of Health (NIH) #Vaccine candidate #Vaccines

Experimental vaccine protects against deadly Sudan virus

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.   SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease. The new vaccine, VSV-SUDV, completely… Read More

#Editor's Choice #News

Colourised scanning electron micrograph of Marburg virus particles
#Immunology / Virology & Vaccines #National Institute of Allergy and Infectious Diseases #Outbreak #Phase I trial #Vaccine candidate

Chimpanzee adenovirus vaccine protects against Marburg virus

An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial.  In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of… Read More

#News

UK
#Association of the British Pharmaceutical Industry #Immunology / Virology & Vaccines #Moderna #mRNA #Pharmaceuticals #Therapeutics

Moderna joins the Association of the British Pharmaceutical Industry 

Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK.  Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines

AI use in repurposing drugs for Covid-19

Listen to this article on the DDW podcast: In 2020, AI models predicted the efficacy of repurposed drugs for Covid-19. Clinical trials revealed eight out of nine predictions were correct. Here Imran S Haque, VP Data Science at Recursion describes the journey of the AI platform behind those predictions. The Covid-19… Read More

#Exclusive Content

Vaccine
#HIV #Immunology / Virology & Vaccines #Janssen #National Institute of Allergy and Infectious Diseases #Phase III trial

Experimental HIV vaccine safe but ineffective

An investigational HIV vaccine regimen was safe but did not provide protection against HIV, an independent data and safety monitoring board (DSMB) has determined.  The regimen was tested among men who have sex with men (MSM) and transgender people. The HPX3002/HVTN 706, or ‘Mosaico’, Phase III clinical… Read More

#News

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA #pDNA

Early phase support for plasmid DNA supply to secure future manufacturing

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and… Read More

#Exclusive Content

Pneumococcal disease vaccine
#Clinical trial #FDA #Immunology / Virology & Vaccines #Pneumonia #Regulatory #United States #Vaxcyte

Breakthrough Therapy designation for pneumococcal disease vaccine

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in… Read More

#News #Regulatory

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

#Clinical trials #Covid-19 #Data #Disease surveillance #Global.health #Immunology / Virology & Vaccines

Fortifying vaccines through disease surveillance and data reporting  

Shelley McLendon, SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. There, McLendon spoke on the topic of fortifying vaccines against future pandemics, specifically discussing: The importance of disease surveillance and reporting with regard to emerging… Read More

#Exclusive Content

Baby on a respirator - RSV
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines #Influenza #OneThree #Poolbeg Pharma #Respiratory syncytial virus

AI identifies drug candidates for respiratory syncytial virus

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV.  The AI programme, part of a collaboration between Poolbeg Pharma and OneThree, uses Poolbeg’s RSV human challenge… Read More

#Editor's Choice #News